Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.

By P. Noble, C. Albera, W. Bradford, U. Costabel, M. Glassberg, D. Kardatzke, T. King, L. Lancaster, S. Sahn, J. Szwarcberg and 2 more. The Lancet, 2011

2,026 citations recorded by the source corpus.

Subfields: Pulmonary and Respiratory Medicine

View Paper: https://www.semanticscholar.org/paper/31fc785d6dcc8bce4eacf77fd61551b0ace9fc48

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Liang Ma
2. P. Fu
3. Rong-shuang Huang

Citations in the corpus

• Kidney fibrosis: from mechanisms to therapeutic medicines (2023, background): “As a small synthetic molecule, pirfenidone is protected against pulmonary fibrosis by the inhibition of TGF-β1 expression.(253,254) What’s more, it is encouraging to find Pirfenidone could restore the eGFR in patients with DKD or FSGS.”